The randomized phase III trial is evaluating two AC dosing schedules followed by paclitaxel in node-positive or high-risk node-negative breast cancer.
The SWOG S0221 randomized phase III investigation compares the efficacy of two AC-based adjuvant chemotherapy regimens after surgical resection for stage I, II, or III breast cancer.
The study is designed to clarify how dosing interval and paclitaxel administration frequency may affect outcomes in high-risk resected disease.